Sihuan Pharmaceutical Holdings Group Ltd. (00460.HK) saw its shares climb over 2% after its subsidiary received approval to begin a late-stage clinical trial for a new drug indication.
The approval, granted by China's National Medical Products Administration, allows Xuanzhu Biopharmaceutical Co., Ltd. (02575.HK) to proceed with a Phase III study of Annerazone Sodium Enteric-coated Tablets, the company said in a statement. Xuanzhu Biopharmaceutical's stock surged more than 12% on the news.
The trial will assess the drug as part of a bismuth-containing quadruple therapy aimed at eradicating Helicobacter pylori, a common bacterial infection linked to stomach ulcers and cancer. Annerazone Sodium was first approved for marketing in China in June 2023 for the treatment of duodenal ulcers.
This new trial represents a significant step toward expanding the drug's approved uses. A successful outcome could open up a substantial new market for Sihuan and Xuanzhu, targeting the large patient population affected by H. pylori infections.
The advancement into a Phase III study de-risks the development pathway for this new indication. For investors, a successful trial and subsequent market approval could provide a significant new revenue stream, potentially boosting the valuation of both Xuanzhu Biopharmaceutical and its parent company, Sihuan Pharmaceutical. The next major catalyst will be the release of top-line data from the Phase III study, though a specific timeline has not yet been disclosed.
This article is for informational purposes only and does not constitute investment advice.
